Core Viewpoint - Tianmu Pharmaceutical's stock has experienced significant fluctuations, with a year-to-date increase of 111.50%, but a recent decline in the last five trading days [1][2]. Financial Performance - For the period from January to September 2025, Tianmu Pharmaceutical achieved a revenue of 159 million yuan, representing a year-on-year growth of 27.48%. The net profit attributable to the parent company was 14.21 million yuan, showing a substantial increase of 484.48% compared to the previous year [2]. Stock Market Activity - As of November 17, Tianmu Pharmaceutical's stock price was 18.57 yuan per share, with a market capitalization of 2.261 billion yuan. The stock saw a trading volume of 46.34 million yuan and a turnover rate of 2.04% [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on August 21, where it recorded a net buy of -55.03 million yuan [1]. Shareholder Information - As of September 30, the number of shareholders for Tianmu Pharmaceutical was 9,693, a decrease of 6.91% from the previous period. The average circulating shares per person increased by 7.42% to 12,557 shares [2]. Business Composition - Tianmu Pharmaceutical's main business revenue composition includes health products (48.01%), circulation goods (23.21%), raw materials (15.98%), traditional Chinese medicine (11.47%), Western medicine (0.89%), training (0.32%), and other (0.12%) [1]. Dividend History - Since its A-share listing, Tianmu Pharmaceutical has distributed a total of 59.63 million yuan in dividends, with no dividends paid in the last three years [3].

Core Viewpoint - Tianmu Pharmaceutical (600671) announced that it plans to provide guarantees for its subsidiaries, with a total amount not exceeding RMB 35 million for the year 2025 [1] Summary by Categories Company Guarantees - The total amount of guarantees provided by the company for its subsidiaries is expected to be up to RMB 35 million for the year 2025 [1] - As of the date of the announcement, the actual external guarantee balance provided by the company and its consolidated subsidiaries is RMB 17.52504 million, which includes the newly added guarantees [1] Financial Impact - The total guarantees represent 334.55% of the company's most recent audited net assets attributable to the parent company's shareholders [1] - The company has not provided any guarantees to its controlling shareholders, actual controllers, or their related parties, amounting to RMB 0 [1] Other Relevant Information - The company has no other external guarantees and there are no overdue guarantees [1]

证券代码：600671 证券简称：天目药业 公告编号：临 2025-052 杭州天目山药业股份有限公司 重要内容提示： 担保对象及基本情况 | 担保 | 被担保人名称 本次担保金额 | "公司"） 6,000.00 万元 | | 杭州天目山药业股份有限公司（以下简称 | | --- | --- | --- | --- | --- | | 对象 | | | | | | | 实际为其提供的担保余额 | - | | | | （一) | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 | ☑否 | □不适用：_________ | | 担保 对象 | 被担保人名称 | | | 青岛天目山健康科技有限公司（以下简称 "青岛天目山"），公司全资子公司 | | | 本次担保金额 | 3,000.00 万元 | | | | | 实际为其提供的担保余额 | 9,280.04 万元 | | | | (二) | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 | ☑否 | □不适用：___ ...

证券代码：600671 证券简称：天目药业 公告编号：临 2025-051 杭州天目山药业股份有限公司 关于子公司取得换发后的《药品生产许可证》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州天目山药业股份有限公司（以下简称"公司"）获悉，公司子公司黄 山天目薄荷药业有限公司（以下简称"黄山薄荷"）于近日收到安徽省药品监 督管理局换发的《药品生产许可证》（许可证编号：皖 20160184），换发后的 《药品生产许可证》有效期至 2030 年 12 月 31 日，具体情况如下： 一、《药品生产许可证》的主要信息 企业名称：黄山天目薄荷药业有限公司 许可证编号：皖 20160184 社会信用代码：913410007935839891 分类码：Dz 注册地址：安徽省黄山市屯溪区黄山九龙低碳经济园区九龙大道 1 号 质量负责人：洪文平 有效期至：2030 年 12 月 31 日 生产地址和生产范围： 安徽省黄山市屯溪区黄山九龙低碳经济园区九龙大道 1 号：原料药（薄荷 脑和薄荷素油）*** 1 二、对公司的影响 本次公司子 ...

证券代码：600671 证券简称：天目药业 公告编号：临 2025-050 杭州天目山药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 17 日 （星期一） 至 11 月 21 日 （星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 tianmuyaoye@126.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 杭州天目山药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 29 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 24 日 （星期 一） 15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行 交流。 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 一、 说明会类型 本次 ...

证券代码：600671 证券简称：天目药业 公告编号：临 2025-049 杭州天目山药业股份有限公司 关于子公司取得换发后的《药品生产许可证》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州天目山药业股份有限公司（以下简称"公司"）获悉，公司全资子公 司黄山市天目药业有限公司（以下简称"黄山天目"）于近日收到安徽省药品 监督管理局换发的《药品生产许可证》（许可证编号：皖 20160182），换发后 的《药品生产许可证》有效期至 2030 年 12 月 31 日，具体情况如下： 一、《药品生产许可证》的主要信息 企业名称：黄山市天目药业有限公司 许可证编号：皖 20160182 社会信用代码：91341000151488891C 分类码：Ahz 注册地址：安徽省黄山市黄山经济开发区翰林路 7 号 有效期至：2030 年 12 月 31 日 生产地址和生产范围： 安徽省黄山市黄山经济开发区翰林路 7 号：硬胶囊剂，口服液，糖浆剂， 片剂，颗粒剂，丸剂（水蜜丸、浓缩丸、水丸）*** 二、对公司的影响 1 本次换发《药品 ...

Core Viewpoint - Tianmu Pharmaceutical's subsidiary has received a renewed drug production license, ensuring its normal operations without significant impact on the company's performance [1] Group 1 - Tianmu Pharmaceutical's wholly-owned subsidiary, Huangshan Tianmu Pharmaceutical Co., Ltd., has been issued a new drug production license by the Anhui Provincial Drug Administration [1] - The license number is皖20160182 and is valid until December 31, 2030 [1] - The renewal of the license guarantees the normal production and operation of the subsidiary [1]

Core Viewpoint - Tianmu Pharmaceutical has shown significant improvement in financial performance for the first three quarters of 2025, with a revenue increase of 27.48% year-on-year and a net profit of 14.21 million yuan, indicating a turnaround from previous losses and ongoing operational enhancements [1][2]. Financial Performance - The company achieved a revenue of 159 million yuan in the first three quarters, reflecting a 27.48% increase compared to the same period last year, driven by the steady recovery of core business and deepening market channel development [2]. - The net profit attributable to shareholders reached 14.21 million yuan, a significant improvement from a loss of 3.70 million yuan in the previous year, indicating enhanced profitability and financial structure optimization [2]. - The equity attributable to shareholders increased by 27.12% year-to-date, reaching 666 million yuan, showcasing the positive impact of the state-owned capital entry in Qingdao [2]. Asset and Investment - As of the end of the reporting period, the total assets of Tianmu Pharmaceutical stood at 430 million yuan, remaining stable compared to the beginning of the year [3]. - The company's construction in progress increased nearly 9.6 times year-on-year to 13.25 million yuan, primarily due to increased investment in the Huangshan Tianmu technology transformation project, indicating accelerated capacity upgrades and technological improvements [3]. Strategic Initiatives - Tianmu Pharmaceutical is advancing the Huangshan Tianmu technology transformation project with a total investment expected to reach 100 million yuan, aiming for production by the end of 2026, which will significantly enhance the extraction capacity and production efficiency of traditional Chinese medicine [4]. - The management has emphasized a focus on three main sectors: traditional Chinese medicine manufacturing, pharmaceutical distribution, and health, while continuing product innovation and resumption of production [4]. - The company has received re-registration approval for 53 drugs, surpassing the total for the entire year of 2024, with successful progress on key products like the pearl eye drops and the launch of extended products in the Tiepi Fengdou series, contributing to long-term growth potential [4]. Industry Outlook - The industry is witnessing a gradual recovery supported by increasing government policy backing for traditional Chinese medicine, with Tianmu Pharmaceutical positioned to benefit from product restructuring and channel optimization [4]. - The company is transitioning from "recovery growth" to "steady quality improvement," laying a solid foundation for sustained growth through optimized industrial layout, strengthened marketing networks, and enhanced governance structures [4].

Core Insights - Tianmu Pharmaceutical (600671.SH) reported a total operating revenue of 159 million yuan for the first three quarters of 2025, representing a year-on-year increase of 27.48% [1] - The net profit attributable to shareholders of the parent company reached 14.21 million yuan, a significant turnaround from a loss of 3.70 million yuan in the same period last year [1] - The basic earnings per share stood at 0.1167 yuan [1]

证券代码：600671 证券简称：天目药业 公告编号：临 2025-048 杭州天目山药业股份有限公司 关于子公司原房屋租赁合同终止及签署新合同 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 杭州天目山药业股份有限公司（以下简称"公司"）控股子公司青岛模 拟医学科技有限公司（以下简称"模拟医学"或者"老模拟"）因经营 调整需要，经与青岛源嘉润物实业有限公司（以下简称"源嘉润物"） 友好协商，提前终止原办公场地的租赁，双方签署《办公场地租赁合同 解除协议》（以下简称"《补充协议》"）。原合同自 2024 年 9 月 7 日至 2027 年 9 月 6 日止，经协商，原租赁合同提前至 2025 年 10 月 27 日终止。 公司全资子公司青岛模拟医学中心有限公司（以下简称"模拟医学中心" 或"新模拟"）为满足生产经营需要，拟租赁源嘉润物位于青岛市崂山 区九水东路 603 号的源嘉生命科技产业园 A#楼 1-3 层房屋用于运营、办 公，租赁面积约为 7,862.71 ㎡，租赁期限 1 年，自 20 ...